ESS Tech occupies the intersection of a genuine technology story and a balance sheet that runs out of runway within the same fiscal year. The iron flow battery pioneer has spent over a decade building a long-duration energy storage franchise, yet the company generated just $73,000 of total revenue in the second quarter of 2026. That number alone tells the whole story of where ESS stands today: a real product, a real customer pipeline, and a capital structure that is running on fumes.
The most consequential recent development is the June 23, 2026 strategic pivot toward sodium-ion battery energy storage systems, announced alongside a letter of intent with Alsym Energy. Management describes early-stage opportunities approaching $1 billion for sodium-ion solutions across data centers, essential infrastructure, and utility markets. The mechanism is straightforward: sodium-ion cells avoid the thermal runaway risk of lithium-ion, use domestically abundant materials, and sidestep the Foreign Entity of Concern restrictions that the One Big Beautiful Bill Act imposed on battery tax credits. The consequence for shareholders is that ESS is betting its remaining capital on a product line that has not yet shipped a single commercial system, while simultaneously winding down the iron flow manufacturing base that generated all of the company's historical revenue.
The main tension is liquidity. The company reported $10.8 million in unrestricted cash at the end of June 2026. The six-month operating burn was $22.4 million. The balance sheet carried a going concern qualification, a $40 million Yorkville promissory note at a 29 percent effective interest rate, and NYSE delisting proceedings on both share price and market capitalization. The combination of these pressures means that any financing raise before year end carries a meaningful probability of being priced at a substantial discount to current market value.
The catalyst that moves the stock in either direction is the conversion of the Alsym Energy letter of intent into a signed commercial contract, and the timing of any follow-on equity or debt offering. The Q3 2026 earnings release and any subsequent capital raise announcements in the September to November window are the near-term events that define the survival probability of the equity.
ESS Tech originated in 2011 as an iron flow battery manufacturer, building on the premise that the transition from a fossil fuel energy system to one dominated by renewables would require batteries derived from earth-abundant materials with long service lives. The company manufactures in Wilsonville, Oregon, and serves utilities, independent power producers, and commercial and industrial customers. The iron flow technology addresses long-duration storage, applications that span hours rather than minutes, and the company holds a meaningful body of patent protection around its iron-based electrochemistry. The strategic positioning is defensible in principle: iron is the fourth most abundant element in the Earth's crust, the flow architecture decouples energy capacity from power output in a way that lithium-ion cannot replicate, and the safety profile is materially better than that of flammable lithium chemistries.
The June 2026 pivot to sodium-ion represents a fundamental reorientation of the company's commercial strategy. Management stated that the sodium-ion product line carries greater near-term revenue potential than the iron flow program, and the company is streamlining its Wilsonville operations to reallocate capital toward sodium-ion development. The company has stated that it continues to develop iron flow technology for long-duration applications, but the priority ordering has inverted. The sodium-ion BESS that ESS is building sources cells from third-party suppliers, and the company manufactures and assembles the battery modules, housings, energy management systems, and other essential components. This is a materially different business model from the vertically integrated iron flow operation, and it carries different margin dynamics and different execution risk.
The customer environment that ESS is entering in 2026 is defined by three structural forces. First, data center construction tied to artificial intelligence workloads is creating a surge in demand for fast-deploying, safe, domestically sourced energy storage that avoids lithium-ion fire and insurance exposure. Second, the One Big Beautiful Bill Act, enacted in July 2025, introduced Foreign Entity of Concern limitations on battery tax credits that effectively close off Chinese-origin supply chains for projects seeking to claim the 45X production tax credit. Third, the Section 45X PTC provides a per-kilowatt-hour credit for battery cells and a separate per-kilowatt-hour credit for battery modules manufactured in the United States, a subsidy that applies to ESS's sodium-ion offering through 2029. The intersection of these three forces is the commercial thesis that underlies the $1 billion in early-stage sodium-ion opportunities that management cited in the June press release.
The competitive set for short and medium duration storage is dominated by established lithium-ion manufacturers with gigafactory-scale production, and ESS enters this market as a new entrant without a track record of commercial sodium-ion shipments. The company's differentiation rests on three pillars: domestic manufacturing that avoids Foreign Entity of Concern restrictions, a safety profile that eliminates thermal runaway, and the 45X tax credit that applies to U.S.-assembled systems. Each of these pillars is real, but each is also vulnerable. Domestic suppliers of sodium-ion cells are still scaling, the safety advantage narrows as lithium-ion manufacturers improve cell chemistry, and the 45X credit begins to phase down after 2029.
The iron flow battery program is the technology franchise that ESS spent over a decade building, and it remains the company's deepest source of intellectual property. The flow architecture separates power, determined by the size of the electrochemical stack, from energy, determined by the volume of the iron-based electrolyte stored in external tanks. This separation means that extending storage duration from four hours to eight hours requires adding more electrolyte rather than adding more cells, a cost structure that lithium-ion cannot replicate. The iron chemistry itself is non-flammable, the electrolyte uses water-based solutions, and the system does not contain lithium, cobalt, or nickel. The company holds a body of patents around its iron flow electrochemistry, and the manufacturing process for the electrolyte is substantially simpler than the cell manufacturing process for lithium-ion. The iron flow program is best suited to long-duration applications, four to twelve hours and beyond, where the cost per kilowatt hour over the system lifetime is competitive with or superior to lithium-ion.
The sodium-ion program is the new commercial engine that the June 2026 pivot is designed to build. ESS sources sodium-ion cells from third-party suppliers and assembles the modules, housings, energy management systems, and container-level integration in its Wilsonville facility. The sodium-ion chemistry offers a meaningful safety advantage over lithium-ion because the cell is inherently less prone to thermal runaway, and the materials are domestically abundant. Sodium is the sixth most abundant element in the Earth's crust, and the supply chain is not concentrated in a single geopolitically sensitive region the way the lithium and cobalt supply chains are. The 45X production tax credit applies to U.S.-manufactured battery cells and modules, and the sodium-ion BESS that ESS is assembling qualifies for that credit through 2029, with a phase down beginning in 2030. The company has announced plans to offer container, rack, and hardware solutions along with digital software offerings to optimize battery and system health, and management described the customer interest for these solutions as exceeding demand expectations with limited outbound marketing.
The moat analysis is where the technology story meets the commercial reality. ESS's iron flow patents are a genuine barrier to entry in the long-duration segment, and the company is one of only a small number of firms in the world with a working iron flow manufacturing process. However, the iron flow program is not the product that the company is currently selling, and the revenue base that it supports has effectively gone to zero as the company winds down existing contracts. The sodium-ion program has no comparable patent moat because the company is a systems integrator rather than a cell manufacturer, and the cell suppliers that provide the core electrochemistry are the same suppliers available to any other integrator. The real competitive advantage in sodium-ion is timing, domestic manufacturing capability, and the 45X credit that applies to the assembled system, and none of these advantages is exclusive. A well-capitalized competitor can replicate the same domestic assembly model, and the 45X credit is available to any U.S.-manufactured battery system that meets the qualification requirements. The moat is therefore thin, and it is a moat that narrows over time as more domestic sodium-ion manufacturing capacity comes online.
The financial statements for the first half of 2026 describe a company in managed decline. Total revenue for the half was $201,000, versus $2.96 million in the comparable prior-year period. The Q2 revenue figure of $73,000 consisted of extended warranty services and customer reimbursements for freight and travel, with no product sales. The company recognized revenue from the sale of Energy Warehouses, Energy Centers, and other equipment in the first half of 2025, primarily to related parties, and that revenue stream has effectively stopped. Cost of revenue was $14.7 million for the six months, driven by depreciation expense related to the abandonment of fixed assets tied to the Energy Base product line and a loss in the benefit from production tax credits. The production tax credit loss had offset cost of revenue in the prior year period. The gross loss stood at $14.5 million, and the ratio against the revenue figure reflects a manufacturing base that is still running but producing almost no product. The consequence for shareholders is that the income statement no longer reflects a company selling batteries; it reflects a company maintaining a factory while waiting for a new product line to reach commercial readiness.
Research and development spending was $4.8 million. Selling and marketing was $0.8 million. General and administrative was $8.8 million. The R&D increase of 23 percent year over year reflects continued investment in the sodium-ion program even as the company reduces cash burn elsewhere. The net loss for the six months was $31.5 million. The per share figure was $1.00 of loss. The share count has grown substantially since the prior year, from 12.9 million to 32.9 million at the balance sheet date. The increase reflects the ATM offering, the rights and direct offering, and the pre-funded warrant issuance that the company executed to raise capital in the first half of the year. The dilution is the price of staying alive, and it is a price that existing shareholders pay in full.
Cash stood at $10.8 million at the balance sheet date, down from the $14.5 million year-end balance. Restricted cash added another $1.7 million, but the unrestricted position against the six-month operating burn means the company has roughly six months of runway if burn continues at the first half pace. Total assets were $32.5 million against total liabilities of $35.2 million. The resulting stockholders' deficit was $2.7 million. The Yorkville promissory note was drawn in full over the past year and carries a high effective interest rate. Its final maturity falls next spring, making it the dominant debt obligation on the balance sheet. The company also has a sale-leaseback financing obligation with a seven year term and a modest effective interest rate. The annual payment obligation on that obligation rises from $1.2 million to $1.7 million by the end of the term.
The going concern disclosure in the Q2 financial statements is the single most important line in the filing. The company states that these uncertainties cause substantial doubt to exist as to its ability to continue as a going concern for 12 months from the issuance of the financial statements, and that the continuation of the company is dependent upon its ability to obtain additional debt or equity financing in the near term. The language is explicit: if the company is unable to raise sufficient capital on acceptable terms, it may be forced to delay or terminate business activities, liquidate assets, or seek protection under Chapter 7 or Chapter 11 of the Bankruptcy Code. The company raised $13.6 million net from the rights and direct offering in the first half of 2026. It also drew $4.9 million from the ATM, and these proceeds are already substantially consumed. The next financing is not an option; it is a requirement for survival.
The forward outlook for ESS Tech is defined by four variables, each of which is a binary or near-binary event that can move the stock dramatically in either direction. The first variable is the conversion of the Alsym Energy letter of intent into a signed commercial contract. A signed contract with a defined volume, price, and delivery schedule would validate the sodium-ion commercial thesis and give the company a revenue base from which to grow. The failure to convert within the next two quarters would confirm that the $1 billion in early-stage opportunities is a pipeline of interest rather than a pipeline of orders, and it would leave the company with no near-term revenue to offset the operating burn.
The second variable is the timing and terms of the next capital raise. The company has roughly six months of cash runway from June 30, 2026. The Yorkville note matures in February 2027. The next financing is therefore not a strategic choice but a survival requirement, and it almost certainly carries a dilution cost. The ATM facility, the rights and direct offering, and the pre-funded warrant structure that the company has used repeatedly in 2025 and 2026 all carry a cost of equity that reflects the going concern risk premium. A raise at current share prices, or below them, would dilute existing holders by a substantial margin and would signal to the market that the company is still in distress even if the raise closes successfully.
The third variable is the NYSE listing compliance process. The company received notice in June 2026 that it failed to meet the minimum share price requirement. Its average closing share price of $0.98 sat below the $1.00 threshold. The cure period runs six months from the notice, and the company has indicated that it is considering a reverse stock split to regain compliance. A reverse split is a mechanical fix that does not change the fundamental value of the company, and the market has repeatedly punished reverse splits as a signal of management's inability to generate organic share price appreciation. However, the failure to regain compliance before the cure period expires triggers delisting proceedings, and the transition to OTC trading would remove the liquidity premium that an NYSE listing provides and would make future financing more expensive.
The fourth variable is the execution of the Wilsonville streamlining plan. The company announced that it is reducing expenses and cash burn to reallocate capital toward sodium-ion, and the $4.3 million in asset abandonment charges in the first half of 2026 is the first visible step in that process. The question is whether the expense reduction is sufficient to extend the cash runway long enough to reach the first commercial sodium-ion revenue, or whether the reduction is too shallow to change the trajectory. The Q3 2026 operating expense line is the data point that answers that question, and it arrives in the October 2026 earnings window.
The most probable downside scenario is a dilutive raise at a discount that preserves the sodium-ion program but transfers a substantial portion of the equity value to new investors. The mechanics of this scenario are well understood: the company announces a follow-on offering, the stock drops on the news, the offering is priced at a discount to the pre-announcement price, and the new capital extends the runway by 12 to 18 months. Existing holders see their ownership percentage decline, but the company survives and continues to execute on the sodium-ion pivot. This is the base case, and it is the scenario that the current share price most likely already prices in to some degree.
The more severe downside scenario is the failure to close a financing on acceptable terms before the cash position reaches a level where the company cannot meet its operating obligations. The Yorkville note matures in February 2027, and a default on that note triggers a rate increase to 18 percent. The effective rate is already at 29 percent. The sale-leaseback obligation has annual payments that begin in earnest in 2027, and the operating lease obligations continue to draw cash. If the company enters a restructuring process, the unsecured creditors, which include the Yorkville note, the sale-leaseback counterparty, and the operating lessors, would have claims on the asset base. The accumulated deficit of $877 million means that the common equity is deeply out of the money in any liquidation scenario, and the probability of total equity loss in a bankruptcy or distressed restructuring is not negligible given the current balance sheet.
The counterargument to the bear case is straightforward and deserves explicit treatment. The sodium-ion opportunity is real, and the demand signal from data center operators is not a management fabrication. The Alsym Energy letter of intent, the customer interest that management described as exceeding demand expectations, and the structural tailwinds from the One Big Beautiful Bill Act and the 45X tax credit all point to a genuine commercial opportunity for domestically sourced, non-lithium energy storage. A company that successfully converts even a fraction of the early-stage sodium-ion pipeline into signed contracts would generate revenue that dwarfs the $201,000 reported in the first half of 2026, and the equity value would reflect that transformation. The risk is that the company does not survive long enough to capture the opportunity, and that is a financing risk, not a technology risk.
The competitive risk is real but is a second-order concern relative to the financing risk. The lithium-ion incumbents are moving into sodium-ion, and the domestic manufacturing capacity for sodium-ion cells is expanding. However, the 45X credit and the Foreign Entity of Concern restrictions create a protected window for U.S.-assembled systems that gives ESS a competitive advantage that is time-limited but meaningful. The window closes as more domestic capacity comes online and as the 45X credit phases down, but the window is open now, and the data center buildout cycle that is driving demand is not a one-year phenomenon.
Valuing ESS Tech requires separating the going concern discount from the technology option value, and the two components move in opposite directions depending on the scenario. The framework is a scenario-weighted valuation anchored on the balance sheet, the financing cost, and the revenue optionality from the sodium-ion pipeline. The balance sheet provides the floor, the financing terms provide the dilution cost, and the sodium-ion pipeline provides the upside that is currently unpriced because it is not yet contracted.
The bear case assumes the company raises a dilutive financing at a 40 percent discount to current prices and the Alsym Energy letter of intent does not convert to a signed contract within the next four quarters. In that scenario, the company survives with a cash position in the range of $15 to $20 million. The share count expands by 50 to 100 percent, and the revenue base remains at the current sub-million level. The equity value in this scenario is effectively the residual value of the iron flow patent portfolio and the Wilsonville manufacturing assets, net of the debt and the going concern discount. The bear case value is below $0.30 per share on a fully diluted basis.
The base case assumes the company completes a dilutive raise that extends the runway to 18 months, and that the Alsym Energy contract converts to a signed agreement. The initial delivery volume generates $5 to $10 million of revenue next year, and the NYSE listing is preserved through a reverse split. In this scenario, the company avoids the most severe dilution but still issues a meaningful number of new shares. The revenue inflection is real but modest, and the operating loss continues to widen as the company scales the sodium-ion program. The base case value is in the range of $0.60 to $1.20 per share on a fully diluted basis, reflecting the going concern premium that the market applies to any equity in this position.
The bull case assumes the Alsym Energy contract converts at scale, at least two additional sodium-ion contracts are signed within the next two quarters, and the company completes a financing on terms that are less punitive than the bear case because the contracted revenue base supports a higher valuation multiple. In this scenario, the company generates $30 to $50 million of revenue next year. The operating loss narrows as the 45X tax credit offsets a portion of the cost of revenue, and the market re-rates the equity from a going concern story to a growth story. The bull case value is in the range of $2.50 to $4.00 per share on a fully diluted basis. The multiple analysis is difficult to apply in a conventional sense because the company has no meaningful revenue and no path to profitability within the valuation period. The relevant comparison is not a public market peer but the implied valuation that a sophisticated investor would assign to a company with $1 billion in early-stage opportunities, a domestic manufacturing base, a 45X tax credit tailwind, and a six month cash runway. The implied multiple is a function of the probability of contract conversion, the timing of the revenue, and the dilution cost of the next financing, and all three of those variables are unresolved as of the Q2 2026 reporting date.
ESS Tech is a company with a real technology, a real customer signal, and a balance sheet that is three months from a crisis. The iron flow battery program is a genuine long-duration energy storage asset, and the patent portfolio is the company's most durable source of value. However, the iron flow program is not the product that generates revenue today, and it is not the product that the company is prioritizing going forward. The sodium-ion pivot is the correct strategic call given the demand environment, the 45X tax credit, and the Foreign Entity of Concern restrictions, but it is also a bet that the company has not yet proven it can execute. The $1 billion in early-stage opportunities is a meaningful signal, but it is not a signed contract, and the difference between the two is the difference between a growth story and a going concern story.
The three thesis variables that define the investment are the Alsym Energy contract conversion, the terms of the next financing, and the depth of the Wilsonville expense reduction. Each of these is a binary event that arrives in the next two to three quarters, and the stock price is a function of the probability distribution across the three. The current share price, at sub-dollar levels, already reflects a high probability of significant dilution and a meaningful probability of a distressed outcome. The equity is therefore a leveraged bet on the sodium-ion pipeline converting faster than the cash runs out, and the leverage is provided by the balance sheet, not by a credit market.
The judgment is that the risk-reward is asymmetric in favor of the downside for holders at current prices, and that is not because the technology is weak but because the financing cost is so high and the time horizon is so short. A company that generates $201,000 of revenue in a six month period and carries a large secured note at a high effective interest rate is not a company that can afford to be wrong about the sodium-ion timeline. The iron flow legacy is a real asset, but it is an asset that is currently generating no revenue and consuming maintenance costs. The sodium-ion program is a real opportunity, but it is an opportunity that requires funding before the company can capture it. The intersection of those two facts is the entire investment case, and it is an uncomfortable intersection to hold.
The appropriate framing for this equity is not a value or a growth label but an option label. The common stock is a call option on the sodium-ion contract conversion, written by the company on its own balance sheet, with a strike price that is the next dilutive financing. The option has a short expiration, the underlying asset is unproven, and the option premium, which is the equity value, is determined by the probability that the company survives to exercise. That is the honest description of what a GWH share is in September 2026, and it is a description that does not flatter the holding.